Regen BioPharma Inks Deal with NCATS an Agency of the National Institutes of Health (NIH) US Govt

Via Small Cap Solutions, LLC We told you be patient with $RGBP that bigger things were coming Well this week that day has Finally Come ! RGBP Announced the FDA Cleared HemaXellerate and the Initiation of and for Human/Patient Clinical Trials Their Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6 Validated that Leads to Rendering Mailignant Cancer Cells Benign (Company Augments Intellectual Property Portfolio by Filing Broad Patent Claims Covering New Biochemical Validation Data) Form 8-K for REGEN BIOPHARMA INC 17-Dec-2015 Entry into a Material Definitive Agreement Item 1.01 Entry Into A Material Definitive Agreement On December 15, 2015 Regen Biopharma, Inc. ( Regen ) entered into an agreement ( Agreement ) with the National Center for Advancing Translational Sciences ( NCATS ), which is a component of the National Institutes of Health ( NIH ), an agency of the U.S. Department of Health and Human Services , pursuant to the following terms and condition


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: